Lipid metabolism correction with statins and probiotics

The gut microbiota can be regarded as a novel “metabolic organ,” involved in the regulation of metabolism. In the case of gut dysbiosis, changes in the concentration of certain bacterial metabolites can act as triggers for the development of metabolic and lipid metabolism disorders. For instance, lower levels of bacteria that produce short-chain fatty acids (SCFA), disorders of enterohepatic circulation of bile acids, elevated levels of trimethylamine (TMA)-producing gut bacteria play an important role in dyslipidemia. Undoubtedly, there are interactions between statin use and changes in the gut microbiota. The paper presents a analysis of the literature data and the results of own research concerning the effect of statins and probiotics on the lipid metabolism and on the microbiota. Considering the positive effects of some probiotics on lipid metabolism, their ability to counteract low-grade inflammation, immunomodulatory role and benefit influence on the digestive system, combining statins with specific probiotic agents appears to be a logical approach. Autoprobiotics (indigenous apathogenic benefit strains) are method of personalized therapy. They demonstrate promising results in the treatment of lipid metabolism disorders. We emphasize that autoprobiotics may be preferable over probiotics due to their safety and longer-lasting effect in the case of personalized therapy of lipid metabolism disorders. However, further research is warranted to gain a deeper understanding of the underlying mechanisms interaction of organism their microbiota including during statin, probiotic and autoprobiotic therapy patients with metabolic syndrome. in the influences and address remaining questions in this field.